EUVIMEDEUVIMED entdecken
Crossref

Multicolor Amplification-Free RNA Detection with Cas13a and Cas13b

Hajime Shinoda, Asami Makino, Mami Yoshimura, Noriko Minagawa, Tatsuya Iida iD, Masahiro Nakano, Takeshi Noda, Masashi Toyoda, Rikiya Watanabe iD

Analytical Chemistry · 17.02.2026 · 98 (6) · 4705-4714

DOI: 10.1021/acs.analchem.5c06305 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Analytical Chemistry, online erschienen am 03.02.2026. Verfasst von Hajime Shinoda und 8 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Physiology Laboratory, Pioneering Research Institute, RIKEN, Wako, Saitama 351-0198, Japan. Hauptthemen laut MEDLINE: RNA, Viral, SARS-CoV-2, Influenza A virus, COVID-19. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Core Research for Evolutional Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The COVID-19 pandemic and recurring outbreaks of infectious diseases underscore the urgent demand for multiplex diagnostics capable of rapid and accurate pathogen identification. Although multiplex nucleic acid amplification tests (NAATs) are widely used for diagnosing diverse infectious diseases, their inherent amplification bias and long turnaround times highlight the demand for faster and reliable alternatives. Here, we present multicolor SATORI (mSATORI), an amplification-free single-molecule genetic test that leverages the complementary activities of CRISPR-Cas13a and Cas13b to achieve simultaneous detection of dual RNA targets. mSATORI identified Influenza A and SARS-CoV-2 RNAs within ∼10 min, with analytical limits of detection (LoD) of 86 aM and 52 aM, respectively. Validation using clinical specimens demonstrated robust diagnostic performance, achieving femtomolar limits of detection (550 aM for Influenza A and 640 aM for SARS-CoV-2), along with sensitivities exceeding 80% and specificities of 100%. Collectively, these results establish mSATORI as a platform for next-generation molecular diagnostics, with broad implications for clinical implementation, outbreak preparedness, and global infectious disease surveillance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, ViralSARS-CoV-2Influenza A virusCOVID-19CRISPR-Associated ProteinsHumansNucleic Acid Amplification TechniquesCRISPR-Cas SystemsLimit of DetectionRapid Diagnostic Tests

Substanzen

RNA, ViralCRISPR-Associated Proteins

Autor:innen und Institutionen

  • Molecular Physiology Laboratory, Pioneering Research Institute, RIKEN, Wako, Saitama 351-0198, Japan.
  • Institute for Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
  • Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo 173-0015, Japan.

ORCID-Profile: Tatsuya Iida, Rikiya Watanabe

Förderung

  • Core Research for Evolutional Science and Technology

Zitieren

APA

Shinoda, H., Makino, A., Yoshimura, M., Minagawa, N., Iida, T., Nakano, M., Noda, T., Toyoda, M., & Watanabe, R. (2026). Multicolor Amplification-Free RNA Detection with Cas13a and Cas13b. Analytical Chemistry, 98(6), 4705-4714. https://doi.org/10.1021/acs.analchem.5c06305

Vancouver

Shinoda H, Makino A, Yoshimura M, Minagawa N, Iida T, Nakano M, et al. Multicolor Amplification-Free RNA Detection with Cas13a and Cas13b. Analytical Chemistry. 2026;98(6):4705-4714. doi:10.1021/acs.analchem.5c06305

BibTeX
@article{Shinoda2026,
  author = {Shinoda, Hajime and Makino, Asami and Yoshimura, Mami and Minagawa, Noriko and Iida, Tatsuya and Nakano, Masahiro and Noda, Takeshi and Toyoda, Masashi and Watanabe, Rikiya},
  title = {Multicolor Amplification-Free RNA Detection with Cas13a and Cas13b},
  journal = {Analytical Chemistry},
  year = {2026},
  volume = {98},
  number = {6},
  pages = {4705--4714},
  doi = {10.1021/acs.analchem.5c06305}
}
Kostenlos starten →